Table 1.
Baseline characteristics of 1,049 anti-HCV-positive women evaluated for presence and level of HCV viremia
| No. of participants (%) |
||
|---|---|---|
| HIV(+) (n=882) | HIV(−) (n=167) | |
| Age (years) | ||
| <35 | 197 (22%) | 51 (31%) |
| >35 | 685 (78%) | 116 (69%) |
| Race | ||
| White | 157 (18%) | 30 (18%) |
| Hispanic | 172 (19%) | 45 (27%) |
| Black | 534 (61%) | 87 (52%) |
| Other | 19 (2%) | 5 (3%) |
| Education | ||
| <12 yrs | 385 (44%) | 80 (48%) |
| ≥12 yrs | 497 (56%) | 87 (52%) |
| History of drug use | ||
| No | 70 (8%) | 9 (5%) |
| Yes | 812 (92%) | 158 (95%) |
| Injection drug use in last 6 months | ||
| No | 683 (77%) | 111 (66%) |
| Yes | 196 (22%) | 56 (34%) |
| Missing | 3 (<1%) | 0 (0%) |
| HBV status | ||
| Seronegative | 98 (11%) | 37 (22%) |
| Seropositivea | 637 (72%) | 97 (58%) |
| Missing | 147 (17%) | 33 (20%) |
| HCV plasma RNA status | ||
| HCV RNA(−) | 159 (18%) | 38 (23%) |
| HCV RNA(+) | 723 (82%) | 129 (77%) |
| HCV plasma RNA (log10 copies/ml) | ||
| (HCV RNA+ only) | ||
| <5.0 | 61 (8%) | 27 (21%) |
| 5.0–7.0 | 601 (83%) | 95 (74%) |
| >7.0 | 61 (8%) | 7 (5%) |
| AIDS diagnosis (HIV+ only) | ||
| No | 556 (63%) | |
| Yes | 326 (37%) | |
| HIV therapy (HIV+ only) | ||
| None | 336 (38%) | |
| Mono | 287 (33%) | |
| Combo | 225 (26%) | |
| HAART | 32 (4%) | |
| Missing | 2 (<1%) | |
a
Defined as presence of any marker: HBsAg, anti-HBc, anti-HBs